epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-118, Phase II. In start-up
Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
QTLs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Missing primary endpoint dataEvidence grade A
2
3
Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Lost to follow-up or withdrew consentEvidence grade A
2
3
Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? Three or more
Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? Three or more; Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? Three or more
Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? Three or more
Too early to judge% of patients; benchmark median 7.9%
The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent
Too early to judge% of patients; benchmark median 3.7%
epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Stopped study treatment early
Too early to judge% of patients; benchmark median 10.7%
epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power
Ineligible patients randomised
Too early to judge% of patients; benchmark median 3.2%
Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).
Breaches and decisions
No QTL in EPI-118 has passed its early-warning line, so nothing needs evaluating.
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.